Showing results (121-130 of 227) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studiesB Uziely, S Jeffers, R Isacson, et al.
British Journal of Cancer|February 1, 1994
Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatinG Los, M J van Vugt, H M Pinedo
Epilepsy & Behavior : E&B|October 16, 2007
A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsyEric H Kossoff, Jenna G Los, Dana F Boatman
Anti-Cancer Drugs|June 1, 1992
High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancersF M Muggia, T D Brown, P J Goodman, et al.
Anticancer Research|January 1, 1981
Clinical trials with diglycoaldehyde (NSC-118994): review and reasons for withdrawal from clinical trialD F Chiuten, G J Vosika, M T Shaw, et al.
Cancer Treatment Reports|September 1, 1979
Toxic effects of cis-dichlorodiammineplatinum(II) in manD D Von Hoff, R Schilsky, C M Reichert, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 1996
Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacologyS C Formenti, P N Shrivastava, M Sapozink, et al.
Cancer Treatment Reports|March 1, 1987
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancerF M Muggia, F J Camacho, B H Kaplan, et al.
Cancer Treatment Reports|August 1, 1977
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agentsD D Von Hoff, M Rozencweig, W T Soper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1984
Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastineL J Laubenstein, R L Krigel, C M Odajnyk, et al.
Pageof 23